Process engineering and MMC: a Design to Value approach

Some might say that it is the role of the client to understand their process and of course that is correct.

Mainstream climate thinking that assumes countries will shut down their coal plants is not realistic.Most coal plants are young: more than half are less than 14 years old.

Process engineering and MMC: a Design to Value approach

Existing coal-fired power plants have enormous value in terms of established markets for their power, grid connections, access to cooling water and experienced personnel necessary for the generation and distribution of power..But even though coal plants themselves are the largest single source of carbon, they can also act as flexible generators, complementing renewables in support of delivering reliable, affordable, and resilient electricity grids.Installing advanced heat sources, such as small modular reactors (SMRs), to replace the coal-fired boilers at existing coal plants will enable the continued use of existing infrastructure for emissions-free electricity generation, providing substantial help with our decarbonisation efforts.. Repowering coal offers a fast, low-risk, large-scale contribution to decarbonising the world’s power generation..

Process engineering and MMC: a Design to Value approach

So, together with Terra Praxis, other specialists and key stakeholders, we are developing a solution that will contribute to creating a huge market for rapid, low-cost repowering of coal and gas plants with carbon-free advanced heat sources, while delivering a substantial portion of the clean electricity required to help achieve Net Zero by 2050.. 18.The answer is nuclear.

Process engineering and MMC: a Design to Value approach

We are facing a climate crisis, and a rapidly closing window of opportunity in which to address it.

The terms of the debate, where ‘nuclear’ is used to cover old technology and its associated problems, must be updated.It is also worth saying that the results have not been modelled where there are lower risk profiles than those of bringing new pharmaceutical products to market.. Let me start with a first curve.. M. odelled.

a scenario where the revenue value of the new products was very high.you can see that scale has little relative influence over the NPV at different scales.

There is a difference, smaller scale has a lower return and somewhere the scale can be optimised, but changes are relatively small and would suggest that sticking with an installed or familiar scale may make sense, if you are confident that most of your products will be blockbusters..There is a natural upper limit to the.